Last reviewed · How we verify
Q/LAIV-BFS (MEDI8662)
Q/LAIV-BFS is a quadrivalent live attenuated influenza vaccine formulated in a pre-filled, single-dose applicator for intranasal administration.
Q/LAIV-BFS is a quadrivalent live attenuated influenza vaccine formulated in a pre-filled, single-dose applicator for intranasal administration. Used for Prevention of influenza A and B in children and adults.
At a glance
| Generic name | Q/LAIV-BFS (MEDI8662) |
|---|---|
| Sponsor | MedImmune LLC |
| Drug class | Live attenuated influenza vaccine (LAIV) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This vaccine contains four live, temperature-sensitive attenuated influenza virus strains (two influenza A and two influenza B) that replicate in the cooler upper respiratory tract but not in the warmer lower respiratory tract, inducing mucosal and systemic immune responses. The BFS (blow-fill-seal) technology provides a pre-filled, ready-to-use single-dose device that improves convenience and reduces preparation steps compared to traditional multi-dose vials.
Approved indications
- Prevention of influenza A and B in children and adults
Common side effects
- Nasal congestion
- Runny nose
- Sore throat
- Cough
- Fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Q/LAIV-BFS (MEDI8662) CI brief — competitive landscape report
- Q/LAIV-BFS (MEDI8662) updates RSS · CI watch RSS
- MedImmune LLC portfolio CI